BenevolentAI Investor Conference Presentation Deck
Proven to enhance drug discovery
DISEASE-AGNOSTIC
We can work on any therapeutic
area due to the breadth and
diversity of our data
foundations.
ACCELERATES
DISCOVERY
By combining our Al Platform,
scientific expertise and wet lab
facilities, we accelerate discovery
and reduce discovery and
development timelines.
MODALITY-AGNOSTIC
The Benevolent Platform™ can
be applied to antibody and
biologic targets, in addition to
small molecule targets.
IDENTIFIES NOVEL
TARGETS
Our predictive tools can
surface targets that have never
been considered for a disease
before.
BUILT FOR SCALE
Our scalable and versatile
Platform can support multiple
in-house drug programmes
and commercial collaborations.
POTENTIAL TO INCREASE
PROBABILITY OF SUCCESS
By building higher confidence
hypotheses in the earliest
stages of drug discovery, we
aim to reduce costly failures
down the line.
Benevolent 15View entire presentation